
دجابر
داروسازی جابرابنحیان
ناکافی
تریدر | نوع سیگنال | حد سود/ضرر | زمان انتشار | مشاهده پیام |
---|---|---|---|---|
![]() بورس/سود/زیانRank: 324 نیاز به اشتراک | خرید | حد سود: تعیین نشده حد ضرر: تعیین نشده نیاز به اشتراک | 5/27/2025 | نیاز به اشتراک |
نیاز به اشتراک | خرید | حد سود: تعیین نشده حد ضرر: تعیین نشده نیاز به اشتراک | 5/31/2021 | نیاز به اشتراک |
![]() شرکت گروه سرمایه گذاری سایپاRank: 46 نیاز به اشتراک | خرید | حد سود: تعیین نشده حد ضرر: تعیین نشده نیاز به اشتراک | 2/15/2021 | نیاز به اشتراک |
![]() بورس نوسانRank: 743 | خرید | حد سود: ۱۴٬۴۱۹ حد ضرر: تعیین نشده | 1/26/2025 | |
![]() 卍卍 نوسانگیران بورس 卍卍Rank: 3436 | خرید | حد سود: تعیین نشده حد ضرر: تعیین نشده | 8/10/2025 |
Adjusted Price Chart of دجابر and دجابر Signal Trend
سود 3 Months :
Who made the most profit from دجابر?
mehdi4000

اقتصاد امروز « مهندس صلواتی »
razhanm.m

نوسان گیری مدرن

Bazigaranesaham
سیگنالهای دجابر
Filter
Signal Type
Trader Type
Time Frame
نوع پیام

بورس طارم
#Group sales report #medicine In August 1404, pharmaceutical companies sold 18259 billion tomans, which increased by 50 % compared to the same year last year. 💵 Export sales of 332 billion tomans, which increased by 76 percent from the same year. #Dezagress Company registered the highest export with 116 billion USD. ✅ #Broadcasting Company with 3602 billion USD had the highest sales in the company. The following companies recorded the highest growth rate compared to the same year. #1124% K_B_S #204% #145%Dabor #129% medicine #123%late #116% Daller #107% Dekimi #Caspian 105%🔥 #Degree 103% #93%Valley #91% Long #Debacco 88%🔥 #Dafra 76% #76% detection #71%🔥 #68% Broadcast #58% Dezagress #Damidid 58% #57% decay #56% dendina #50% decline #49% Defense #47% Decoration #Depars 45%🔥 #Dana 33%🔥 #Deller 33% #32% Dasouh #30% Dehravi #18% Hijra #3% dock #2% Deanko #Dajaber 1% #Dhavi 🔥 (First Year of Report) #Dashiri (first year of report) 📅 Last Update: 1404/06/13 Support your shares by submitting this report in groups @dndir

نرم افزار تحلیل گر بورس - دایموند
#Group sales report #medicine In August 1404, pharmaceutical companies sold 18259 billion tomans, which increased by 50 % compared to the same year last year. 💵 Export sales of 332 billion tomans, which increased by 76 percent from the same year. #Dezagress Company registered the highest export with 116 billion USD. ✅ #Broadcasting Company with 3602 billion USD had the highest sales in the company. The following companies recorded the highest growth rate compared to the same year. #1124% K_B_S #204% #145%Dabor #129% medicine #123%late #116% Daller #107% Dekimi #Caspian 105%🔥 #Degree 103% #93%Valley #91% Long #Debacco 88%🔥 #Dafra 76% #76% detection #71%🔥 #68% Broadcast #58% Dezagress #Damidid 58% #57% decay #56% dendina #50% decline #49% Defense #47% Decoration #Depars 45%🔥 #Dana 33%🔥 #Deller 33% #32% Dasouh #30% Dehravi #18% Hijra #3% dock #2% Deanko #Dajaber 1% #Dhavi 🔥 (First Year of Report) #Dashiri (first year of report) 📅 Last Update: 1404/16/13 Support your shares by submitting this report in groups @dndir
#Dajaber Information and #More_Manic Failures #Courses_6_Maine to 1404/03/31 (Audited) ▪️ Jabir Ibn Hayan's pharmaceutical company has identified 786 riyals per share of 786 Rials per share, which decreased by 53 % compared to the same period last year. ▪️ Djaber with a registered capital of 2,268,000 million Rials during the six -month performance ending to 140/03/31 has identified 1,782,770 million rials. ▪️ The company identified 1,551,344 million riyals of profit, which is 67 percent compared to the same period last year. 1404-06-12 15:52:21 (1398784) ایرین ایرین @codal360_ir
# #Dajaber 💹 @tse_plus 📅 1404/6/12 ⌚ 12:29:08 🔖 8,500 #Purchase 1 real code in the case of 2.53 panels Valued at 4,732,477,000 Rials

بورسی های گیلان
#Medication (2) monthly ❇️ 5 months performance to 5 months 403 (Billion USD) ●#Dajabar income [602 MT] 6% drop ●#Biotics Income [742 MT] Growth 23% Growth ● #Darm Revenue [432 MT] Growth 40% ●#Income Revenue [503 MT] Growth 32% ●#Dekimi Income [394 MT] Growth 48% Growth ●#KBC Revenue [268m] Growth 307% ●#Long revenue [4,980mm] 2% drop ●#Claimer Income [826 MT] Growth 121% ●#Disaster Revenue [963 MT] Growth 42% Growth ●#Dabor Revenue [1,410 MT] Growth 55% ●#Daine of Income [158m] Growth 41% ●#24% Growth Income [484 MT] ●#53% growth in revenue [583 MT] ●#Lolk Income [941m] Growth 67% ●#Deanco Income [249 MT] Growth 9% Growth ●#Delibal Revenue [449 MT] Growth 84% Growth ●#Dasouh Revenue [341m] 12% Growth ●#Druz income [182m] 15% drop ●#Income Income [333m] Growth 71% ●#Di in Revenue [293 MT] Growth 35% Growth
#Dajaber #Report_Connaire #course_1_14/14/05/31 #Pharmaceutical_jabar_Ban_Harian ▪️ Jaber Ibn Hayan Pharmaceutical Company has sold its products from 1,443,287 million rials during the 1 -month performance ending 140/05/31, which has grown by 1 % compared to the same period last year. ▪️ Dajaber with a registered capital of 2,268,000 million Rials over the 8 -month performance of the fiscal year ended 1404/09/30 amounted to 9,540,403 million riyals, which increased by 3 % compared to the same period last year. 1404-06-09 17:17:24 (1400159) ایرین ایرین @codal360_ir
#Dajaber #Report_Connaire #course_1_14/04/31 (amendment) #Pharmaceutical_jabar_Ban_Harian ▪️ Jabir Ibn Hayan Pharmaceutical Company has sold its products of 1,400,054 million rials during the 1 -month performance ending 140/04/31, which has grown by 4 % compared to the same period last year. ▪️ Dajaber with a registered capital of 2,268,000 million Rials over the 7 -month performance of the fiscal year ended 1404/09/30 at 8,097,116 million riyals, which increased by 3 % compared to the same period last year. 1404-06-09 13:58:02 (1399617) ایرین ایرین @codal360_ir

بورس طارم
#Declaration #Dejaber #Dezravi #Biotics #Decorations #Daddy #Kib_S #Diran #Desthi #Drug #Drug #Dahavi #Hijra #Deli #Caspian #Dekimi #Dadam #Dadam #Dalbari #Dasta #Deller #Deller # #Domain #Deco -Dafara #Defara #Dehz #Dafra #Defara #Department #Dabid #Dasouh #Deanko #Richmak #Dabur اری Important financial ratios in the drug and pharmaceutical product group (Spring 1404) - Latest Financial Statement Published The Best Profit Margin Ratio: Caspian, Decoration, Dafra, Dezina, Design The best ratio of profit margins: Defra, Deafra, Dashiri, Dezagress, Caspian The lowest ratio of P/E TTM: Dajaber, Dashiri, Player, Dezagress The least debt ratio: Defra, Dahad, Dahawi Most of the Returns' Returns: Dashiri, Dabur, Caspian Increasing the profit margin compared to the previous season: Devil, Detection, Dezravi, Biotics, Decorations, Drugs, Longness, Longness, Dadam, Dazguz, Dana, Dana, Damin, Dafara, Dalc, Dasoum, Dasouh, Dabor

بورس طارم
#Declaration #Dejaber #Dezravi #Biotics #Decorations #Daddy #Kib_S #Diran #Desthi #Drug #Drug #Dahavi #Hijra #Deli #Caspian #Dekimi #Dadam #Dadam #Dalbari #Dasta #Deller #Deller # #Domain #Deco -Dafara #Defara #Dehz #Dafra #Defara #Department #Dabid #Dasouh #Deanko #Richmak #Dabur اری Important financial ratios in the drug and pharmaceutical product group (Spring 1404) - Latest Financial Statement Published The Best Profit Margin Ratio: Caspian, Decoration, Dafra, Dezina, Design The best ratio of profit margins: Defra, Deafra, Dashiri, Dezagress, Caspian The lowest ratio of P/E TTM: Dajaber, Dashiri, Player, Dezagress The least debt ratio: Defra, Dahad, Dahawi Most of the Returns' Returns: Dashiri, Dabur, Caspian Increasing the profit margin compared to the previous season: Devil, Detection, Dezravi, Biotics, Decorations, Drugs, Longness, Longness, Dadam, Dazguz, Dana, Dana, Damin, Dafara, Dalc, Dasoum, Dasouh, Dabor
#Dajaber #Report_Connaire #course_1_14/14/03/31 ▪️ Jabir Ibn Hayan Pharmaceutical Company has sold its products of 810,471 million rials during the 1 -month performance ending 140/03/31, a 52 % drop compared to the same period last year. ▪️ Dajaber with a registered capital of 2,268,000 million Rials over the six -month performance of the fiscal year ended 140/09/30, 6,697,062 million riyals, which increased by 3 % compared to the same period last year. 1404-06-08 11:42:55 (1399200) ایرین ایرین @codal360_ir
Disclaimer
Any content and materials included in Sahmeto's website and official communication channels are a compilation of personal opinions and analyses and are not binding. They do not constitute any recommendation for buying, selling, entering or exiting the stock market and cryptocurrency market. Also, all news and analyses included in the website and channels are merely republished information from official and unofficial domestic and foreign sources, and it is obvious that users of the said content are responsible for following up and ensuring the authenticity and accuracy of the materials. Therefore, while disclaiming responsibility, it is declared that the responsibility for any decision-making, action, and potential profit and loss in the capital market and cryptocurrency market lies with the trader.